t.karlsen

TL2 · Hyderabad

Contributes reviews on supplier material. Based in Hyderabad.

Joined 27 September 2025 · last posted 3d

76 posts, newest first. Showing up to 150.

eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #36 · Clinical › Bloodwork · 25 Jul 2026 · 30 likes An update on my earlier egfr fluctuation post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #137 · Practice › Reconstitution · 23 Jul 2026 · 1 like Where I part company with post #135, and it is a narrow parting. Over-dilution: if your target dose is 0.25 mg and your syringe is a 1 mL insulin syringe, you need a…
Retatrutide mass and identity: what a report should show Replied, post #15 · Compounds › Retatrutide · 11 Jul 2026 · 0 likes I think the retatrutide mass and identity question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Forced degradation studies: designing one that is informative Replied, post #85 · Analytics › Method validation · 26 Jun 2026 · 6 likes The documentation on forced degradation studies is better than this thread and I say that as someone who has posted in the thread.
Revisiting: What pooling buys you and what it destroys Replied, post #66 · Evidence › Meta-analyses · 24 Jun 2026 · 0 likes My position on pooling buys is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Retatrutide mass and identity: what a report should show Replied, post #2 · Compounds › Retatrutide · 21 Jun 2026 · 24 likes On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and…
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #68 · Practice › Storage & stability · 6 Jun 2026 · 4 likes No notes. Posting so the count is not one.
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #54 · Practice › Interactions · 30 May 2026 · 0 likes Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people. That is the…
An appeal that succeeded, with the letter structure — the long version Replied, post #23 · Access › Insurance & coverage · 28 May 2026 · 18 likes Nobody has said the unglamorous part of appeal yet, so: most of the variation is explained by things that are boring to write about and easy to check.
A calculator that gives a right answer to the wrong question Replied, post #23 · Data & Tools › Calculators · 24 May 2026 · 22 likes Where a calculator and your own arithmetic disagree, the productive move is to find which step differs rather than to decide which is right. Not a strong opinion, just…
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #101 · Practice › Interactions · 7 May 2026 · 5 likes Oral medications versus time: if you take an oral medication 30 minutes before semaglutide (which slows gastric emptying), the delayed stomach emptying affects when and…
Spike-and-recover accuracy for a peptide assay Replied, post #127 · Analytics › Method validation · 11 Apr 2026 · 32 likes Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of assurance. Almost nothing discussed here has one. If that is already…
What a certificate commits its issuer to — one year on Replied, post #38 · Analytics › COA interpretation · 26 Mar 2026 · 18 likes Post #35 answers the question as asked. The question underneath it is different. Residual solvent screening is not standard on these documents and its presence is a…
Designing a personal experiment that could change your mind — one year on Replied, post #23 · Research Methods › N-of-1 designs · 20 Mar 2026 · 9 likes Everything in post #20 holds. The case it does not cover is the one I have. I would call the community position on Designing a personal experiment likely rather than…
Second pass at: The topic list is dense — is that deliberate? Replied, post #95 · Meta › Site feedback · 10 Mar 2026 · 1 like Performance: if pages are slow to load, timeouts occur, or the site is unresponsive, that is worth reporting with details (when, which pages, how slow).
[2026 update] Regional warehouse stock versus direct despatch Replied, post #9 · Sourcing › Logistics · 2 Mar 2026 · 14 likes Regional warehouse stock versus direct is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles…
Peer-to-peer review: what actually happens on the call — one year on Replied, post #5 · Access › Insurance & coverage · 1 Mar 2026 · 3 likes Everything in post #3 holds. The case it does not cover is the one I have. A clinician's supporting letter that addresses the criteria explicitly is worth considerably…
Preprint servers and what screening they do Replied, post #59 · Evidence › Preprints · 17 Feb 2026 · 5 likes Post #56 answers the question as asked. The question underneath it is different. Version numbers on a preprint server matter. Citing version one of something now on…
Revisiting: A page that has drifted out of date and needs a maintainer Replied, post #70 · Documentation › Wiki requests · 4 Feb 2026 · 5 likes Agreed on all of that, and I have nothing to add to it.
Measurement error in home scales, with a worked standard deviation Started this topic · Research Methods › Statistics · 30 Jan 2026 · 11 likes Measurement error in home scales, with a worked standard deviation Writing it up because I had to work it out twice and would rather nobody else did. What changes if…
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #19 · Outcomes › Body composition · 27 Jan 2026 · 2 likes Where I part company with post #15, and it is a narrow parting. What I want from this Lean mass preservation thread is the list of things that would need to be true for…
Run-in periods and the population they select Replied, post #56 · Evidence › Trials · 26 Jan 2026 · 10 likes Appreciated. The plain phrasing does more work here than a longer post would.
Pharmacy supply in the UK and the questions you will be asked Replied, post #16 · Regional › UK & Ireland · 21 Jan 2026 · 14 likes Where guidance distinguishes between indications, quoting the indication is essential. The same compound has different positions under different indications. The right…
Muscle cramps: the ordinary causes before the exotic ones Replied, post #90 · Practice › Side effects · 21 Jan 2026 · 32 likes Worth separating muscle cramps as a question about the compound from muscle cramps as a question about the documentation. They get answered by different people and only…
A partial dose because the pen emptied mid-injection Replied, post #68 · Practice › Administration · 9 Jan 2026 · 4 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
Designing a personal experiment that could change your mind — one year on Started this topic · Research Methods › N-of-1 designs · 6 Jan 2026 · 0 likes Designing a personal experiment that could change your mind — one year on — setting out what I have, and where I think it stops being reliable. Two things I would like…
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #30 · Practice › Interactions · 4 Jan 2026 · 1 like Anyone asking an interaction question should list everything, including the things they consider irrelevant. The irrelevant one is the answer more often than chance…
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long… Replied, post #39 · Pharmacology › Receptor biology · 2 Jan 2026 · 10 likes Receptor distribution explains the side-effect profile better than anything else. GLP-1 receptors in the gastrointestinal tract and the area postrema account for most…
Pen mechanics when the cartridge is nearly empty — does this still hold? Replied, post #33 · Devices › Pens & autoinjectors · 23 Dec 2025 · 25 likes Needle installation: some pens require a fresh needle for each injection; others have a single needle that stays attached. Check the design of your pen.
Aggregates and why a purity assay may miss them entirely Replied, post #19 · Analytics › Impurities & related substances · 20 Dec 2025 · 3 likes I would be cautious about generalising from the aggregates example above. It is a good example. It is one example.
Persistent vomiting and the threshold for seeking help Replied, post #87 · Safety › Adverse events · 13 Dec 2025 · 17 likes Narrowing post #86, because the general version has more than one answer. On persistent vomiting: the maintained page in the documentation commons covers the general…
[2026 update] Long-time reader, first-time poster Replied, post #31 · Lounge › Introductions · 7 Dec 2025 · 5 likes If you are arriving from somewhere louder, the pace here will feel slow. A topic can sit for two days and then get a reply that is worth the wait. That is the design…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #20 · Access › Pricing · 20 Nov 2025 · 27 likes Cost per milligram is the only comparison that survives format differences, but even then it needs care. A pen and a vial are not the same product and cannot be…
[2026 update] What steady state means for the decision to escalate Replied, post #123 · Practice › Dosing & titration · 17 Nov 2025 · 1 like Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
Pen dose counters: what a click does and does not guarantee Replied, post #45 · Devices › Pens & autoinjectors · 15 Nov 2025 · 6 likes Comparing cost per milligram between a pen and a vial ignores wastage, dead volume and the number of doses actually obtainable. Cost per delivered dose at your dose is…
Follow-up: The decimal-point error, and the habit that catches it Replied, post #93 · Practice › Reconstitution · 6 Nov 2025 · 6 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does. If that is…
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #37 · Compounds › Semaglutide · 31 Oct 2025 · 24 likes That is a fair summary of where the discussion has got to.
New subcategory: rationale and scope Replied, post #85 · Meta › Announcements · 22 Oct 2025 · 1 like Narrowing post #83, because the general version has more than one answer. The failure mode on new subcategory is boring rather than dramatic. It is almost always the…
New subcategory: rationale and scope Replied, post #64 · Meta › Announcements · 19 Oct 2025 · 11 likes Notifications: watching this subcategory means you receive notifications when announcements are posted. Useful if you want to stay current.
Tracking that stops updating and then resumes — the long version Replied, post #22 · Sourcing › Logistics · 5 Oct 2025 · 21 likes Narrowing post #19, because the general version has more than one answer. Peak periods and public holidays affect this more than any other factor and are entirely…
Interim analyses and stopping rules Started this topic · Evidence › Trials · 20 Sep 2025 · 0 likes Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. Asking about interim analyses and stopping rules…
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #44 · Evidence › Study critique · 13 Sep 2025 · 0 likes I would keep Reverse causation and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them…
[2026 update] US compounding rules and how they changed Replied, post #33 · Regional › North America · 23 Aug 2025 · 3 likes Date every claim in this subcategory. Positions here have moved repeatedly and old posts are read as current. That much is documented. The rest is how I have…
How to read a forest plot, properly, from scratch Replied, post #8 · marked as the solution · Evidence › Trials · 23 Jul 2025 · 22 likes Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between…
Antibiotics and a course of something with delayed emptying Replied, post #86 · Practice › Interactions · 9 Jul 2025 · 0 likes Supplements and herbs: many have no established interaction. Some do. If you are taking something unusual, checking a reference (like a pharmacist) is more useful than…
Checking someone else's arithmetic: a worked example thread Replied, post #61 · Practice › Reconstitution · 26 Jun 2025 · 3 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
A report I filed that turned out to be wrong, and the correction Replied, post #117 · Sourcing › Vendor reports · 23 Jun 2025 · 20 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
Which panel is worth repeating and which is worth ignoring Replied, post #33 · Clinical › Bloodwork · 6 Jun 2025 · 1 like Marking my place. If it changes for me I will come back and say so.
Travel coolers and how long they really hold — the long version Replied, post #18 · Devices › Cold chain · 22 May 2025 · 0 likes The bit of Travel coolers that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will…
Reading an MS report that only gives you a single number Replied, post #76 · Analytics › Mass spectrometry · 11 May 2025 · 5 likes Resolution and mass accuracy are different specifications. An instrument can resolve two species and still assign their masses imprecisely, and the reverse is also…
BPC-157: what the rodent literature actually shows, and what it does not — a second… Replied, post #41 · Compounds › Repair & healing peptides · 3 May 2025 · 19 likes The strongest argument against my own position on BPC-157, stated as well as I can state it, since nobody else has yet.
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #40 · Sourcing › Independent verification · 2 May 2025 · 0 likes A record with four results over sixteen months is a thin record rather than a bad one, and the honest description says which. Reading it again, the caveat matters more…
Follow-up: The lowest dose that does anything: is that a real question? Replied, post #8 · Practice › Dosing & titration · 25 Apr 2025 · 0 likes Titrating on symptoms rather than on the calendar is what most people here actually do. It is defensible, it is not what was studied, and describing it as the protocol…
When to suspect the method rather than the sample Replied, post #113 · Analytics › Method validation · 12 Apr 2025 · 0 likes Post #112 answers the question as asked. The question underneath it is different. The limit of quantitation determines what the impurity table can honestly contain.…
Storing a pen in use versus a pen unopened Replied, post #5 · Devices › Pens & autoinjectors · 29 Mar 2025 · 0 likes Storage after first use: most pens can be stored at room temperature after first use, even if unrefrigerated, for a limited time (often 28 days). Check your specific…
Review: a draft on reconstitution arithmetic, with objections Replied, post #72 · Documentation › Doc review · 24 Mar 2025 · 3 likes Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it for the process to mean anything. A guess, clearly labelled as one.
Coverage for the indication versus for the drug — a second dataset Replied, post #36 · Access › Insurance & coverage · 23 Mar 2025 · 0 likes Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves…
Why cagrilintide alone is discussed so much less than in combination Replied, post #12 · Compounds › Cagrilintide & amylin analogues · 22 Mar 2025 · 4 likes On dosing intervals: the long-acting design supports weekly administration, and the escalation schedules in the published trials are gentler than the compound's potency…
Adducts: sodium, potassium, and the peak you did not expect Replied, post #38 · Analytics › Mass spectrometry · 18 Mar 2025 · 2 likes Thank you — that answers what I came here to find out.
Retatrutide dose escalation in the published trials Replied, post #8 · Compounds › Retatrutide · 12 Mar 2025 · 0 likes I had written a reply contradicting post #6 and deleted it. Here is what survived. Dose escalation in the published trials: the protocols started at lower doses and…
Bleeding at the injection site: normal, and what to do about it — does this still hold? Replied, post #10 · Practice › Administration · 10 Mar 2025 · 20 likes Bleeding at the injection site: normal and usually minimal. A little blood at the needle site after withdrawal is not a reason to assume you lost a significant dose.…
Revisiting: German, French and Dutch differences, compared Replied, post #2 · Regional › European Union · 8 Mar 2025 · 0 likes Counterpoint on German, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Research-use-only status: what it means legally and practically — a second dataset Replied, post #107 · Compounds › Other compounds · 6 Mar 2025 · 13 likes I have no financial interest in anything named in this thread and I want to say so before I comment on Research-use-only status, because it is the sort of subject where…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #138 · Evidence › Journal club · 23 Feb 2025 · 14 likes Post #135 is right about the mechanism and I think understates the practical bit. One more thing on SURPASS-2 that took me far too long to see: the two figures people…
Research-use-only status: what it means legally and practically — a second dataset Replied, post #97 · Compounds › Other compounds · 23 Feb 2025 · 28 likes The claim about Research-use-only status upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says…
Coming back to: Recording a dissent on a document rather than suppressing it Replied, post #12 · Documentation › Doc review · 6 Dec 2024 · 0 likes Confirming post #9 from a second method, which matters more than confirming it from a second person. Recording a dissent: I have looked for the primary source twice and…
Choosing which test to pay for, given a fixed budget — does this still hold? Replied, post #31 · Sourcing › Independent verification · 14 Nov 2024 · 29 likes Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want.
People with a low starting BMI: where the evidence stops Replied, post #15 · Clinical › Special populations · 14 Nov 2024 · 1 like Coming back to post #13, because the follow-up matters more than the original answer. People on multiple medicines are under-represented in trials by design, and that…
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #38 · Compounds › Repair & healing peptides · 12 Nov 2024 · 0 likes What I would want before treating reading a preclinical wound-healing model as settled: the method, the sample, and whether anyone tried to find the opposite result.…
A page that has drifted out of date and needs a maintainer Replied, post #21 · Documentation › Wiki requests · 23 Oct 2024 · 8 likes Name a willing maintainer in the request. Point three of the criteria stops more nominations than the other three combined. I would hold that lightly until someone with…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #5 · Compounds › Tirzepatide · 21 Oct 2024 · 12 likes Injection-site reactions were reported at a low but non-zero rate across the trials. The practical point is that a reaction at one site does not predict a reaction at…
Second pass at: Hoarding and why it makes a shortage worse Replied, post #78 · Access › Shortages · 12 Oct 2024 · 2 likes Both are useful and different. The notice tells you the national position; the account tells you what is happening on the ground. I have written this out at length…
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #68 · Practice › Dosing & titration · 21 Sep 2024 · 0 likes Confirming post #65 from a second method, which matters more than confirming it from a second person. Nothing here is medical advice, and a titration question is one of…
Coming back to: Grapefruit: why this class is not the class that cares Replied, post #8 · Practice › Interactions · 14 Sep 2024 · 15 likes Coming back to post #7, because the follow-up matters more than the original answer. Careful with the language on Grapefruit. "Not detected" and "not present" are…
SURPASS-2 and the comparator dose question that will not go away Replied, post #15 · Compounds › Tirzepatide · 13 Sep 2024 · 0 likes Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that…
The C-cell question: rodent findings and their human context — what changed since Started this topic · Compounds › Semaglutide · 6 Aug 2024 · 37 likes The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if…